High induction dosing of risankizumab in patients with moderate-to-severe plaque psoriasis: Interim results from the phase 2 KNOCKOUT study

被引：0
|
作者：
Blauvelt, A. [1 ]
Gudjonsson, J. [2 ]
Matheson, R. [1 ]
Liu, R. [3 ]
Shi, L. [3 ]
Photowala, H. [3 ]
Ehst, B. [1 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Univ Michigan, Dept Dermatol, Sch Med, Ann Arbor, MI USA
[3] AbbVie Inc, N Chicago, IL USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2023年 / 143卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
LB1703
引用
收藏
页码：B16 / B16
页数：1
相关论文
共 50 条
  • [41] A prospective noninterventional study to evaluate the psychosocial impact of biological treatment outcomes in patients with moderate-to-severe plaque psoriasis in the UK: interim results
    Bewley, Anthony
    Shafi, Mehbub
    Gorecki, Patricia
    Andiappan, Manoharan
    Kleyn, C. Elise
    Hunter, Hamish J. A.
    Shams, Kave
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 224 - 225
  • [42] Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
    Blauvelt, Andrew
    Armstrong, April W.
    Langley, Richard G.
    Gebauer, Kurt
    Thaci, Diamant
    Bagel, Jerry
    Guenther, Lyn C.
    Paul, Carle
    Randazzo, Bruce
    Flavin, Susan
    Hsu, Ming-Chun
    You, Yin
    Reich, Kristian
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2317 - 2324
  • [43] Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with moderate-to-severe plaque psoriasis: Results from the EXCEED study
    Gottlieb, Alice B.
    Merola, Joseph F.
    Reich, Kristian
    Behrens, Frank
    Nash, Peter
    Bao, Weibin
    Pellet, Pascale
    Pricop, Luminita
    McInnes, Iain B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB92 - AB92
  • [44] Maintenance regimen of secukinumab in subjects with moderate-to-severe plaque psoriasis: Results from the OPTIMISE study
    Reich, Kristian
    Puig, Lluis
    Szepietowski, Jacek C.
    Paul, Carle
    Lacour, Jean Philippe
    Tsianakas, Athanasios
    Sieder, Christian
    Rissler, Michael
    Jagiello, Piotr
    Orsenigo, Roberto
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB90 - AB90
  • [45] Effects of apremilast on pruritus in patients with moderate-to-severe plaque psoriasis: results from the ESTEEM 1 and 2 trials
    Papp, K.
    Yosipovitch, G.
    Bagel, J.
    Kircik, L.
    Thaci, D.
    Lambert, J.
    Ferrandiz, C.
    Goodfield, M.
    Hu, C. C.
    Stevens, R.
    Day, R.
    Girolomoni, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (06) : E144 - E145
  • [46] Efficacy and Safety of Ixekizumab in Chinese Patients With Moderate-to-Severe Plaque Psoriasis: 60-Week Results From a Phase 3 Study
    Li Xia
    Zheng Jie
    Pan WeiLi
    Zheng Min
    Lu Yan
    Li FuQiu
    Ding YangFeng
    Zhang JianZhong
    Li HongYing
    Rui WenLong
    国际皮肤性病学杂志（英文）, 2022, 05 (04)
  • [47] Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study
    Rui, Wenlong
    Li, Xia
    Zheng, Jie
    Pan, Weili
    Zheng, Min
    Lu, Yan
    Li, Fuqiu
    Ding, Yangfeng
    Zhang, Jianzhong
    Li, Hongying
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB55 - AB55
  • [48] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
    Gordon, K. B.
    Blauvelt, A.
    Papp, K. A.
    Langley, R. G.
    Luger, T.
    Ohtsuki, M.
    Reich, K.
    Amato, D.
    Ball, S. G.
    Braun, D. K.
    Cameron, G. S.
    Erickson, J.
    Konrad, R. J.
    Muram, T. M.
    Nickoloff, B. J.
    Osuntokun, O. O.
    Secrest, R. J.
    Zhao, F.
    Mallbris, L.
    Leonardi, C. L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04): : 345 - 356
  • [49] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
    Egeberg, Alexander
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (21): : 2101 - 2102
  • [50] Efficacy and safety of risankizumab, an interleukin-23 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis: 16-week results from the phase III IMMhance trial
    Blauvelt, A.
    Papp, K. A.
    Gooderham, M.
    Langley, R. G.
    Leonardi, C.
    Lacour, J. -P.
    Philipp, S.
    Tyring, S.
    Bukhalo, M.
    Wu, J. J.
    Bagel, J.
    Frankel, E. H.
    Pariser, D.
    Flack, M.
    Scherer, J.
    Geng, Z.
    Gu, Y.
    Camez, A.
    Thompson, E. H. Z.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E248 - E248
12345